EAM Investors’s Immune Design Corp. IMDZ Stock Holding History

EAM Investors’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-37,355	Closed	-$387K	–	394
2017 Q3	$387K	Buy	+37,355	New	+$368K	0.05%	288

Other funds holding IMDZ

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM Investors's IMDZ Position: Q4 2017 in Review

EAM Investors sold out of Immune Design Corp. (IMDZ) in Q4 2017, closing a stake of 37,355 shares — an estimated $387K sold.

EAM Investors first reported a position in IMDZ in Q3 2017 and held it in 1 quarter. The position peaked at $387K in Q3 2017. 76 funds tracked by Wall St. Rank hold IMDZ as of Q4 2017.

EAM Investors reported no remaining Immune Design Corp. position as of Q4 2017 after selling out during the quarter.
EAM Investors sold 37,355 Immune Design Corp. shares in Q4 2017, an estimated $387K.
EAM Investors first reported a position in Immune Design Corp. in Q3 2017 and held it in 1 quarter.
EAM Investors's Immune Design Corp. position peaked at $387K in Q3 2017.
76 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.